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Abstract
Purpose The SAGIT instrument is a comprehensive
clinician-reported outcome instrument assessing key fea-
tures of acromegaly: signs and symptoms, associated
comorbidities; growth hormone levels; insulin-like growth
factor-1 levels; and tumor profile. The SAGIT instrument
has been designed to assist endocrinologists managing
acromegaly in practice. Here, we report on pre-testing (to
assess ease of understanding and acceptability) and a pilot
study (to assess relevance, ease of use, and utility in real-
life conditions) (NCT02231593).
Methods For pre-testing, 11 endocrinologists completed
the SAGIT instrument using patient medical records and
were also interviewed. They subsequently completed a
PRAgmatic Content and face validity Test (PRAC-Test)
to report their experiences using SAGIT, and feedback was
used to revise the instrument. In the pilot study, nine
endocrinologists completed the SAGIT instrument in real-
time with patients belonging to three different categories
(stable/controlled, active/uncontrolled acromegaly, treat-
ment-naı¨ve), while four completed the instrument based on
medical-record review. All participants then completed the
PRAC-Test and their feedback was used to update the
instrument.
Results The SAGIT instrument was well accepted by
endocrinologists, with most indicating that it was concise,
practical, easy to understand, useful for assessing treatment
response, and valuable as a component of the patient’s
medical record. The pilot study confirmed the instrument’s
acceptability, utility, and ease of use, and indicated its
potential for distinguishing acromegaly clinical stages.
Conclusions The SAGIT instrument is promising as a
tool for use by endocrinologists in everyday practice to
assess the status and evolution of disease in patients with
acromegaly and to guide treatment decision-making.
Keywords Acromegaly  Clinician-reported outcomes 
Instrument  Pilot study
Introduction
Acromegaly is a chronic multisystem disease resulting
from the oversecretion of growth hormone (GH), which is
usually caused by a pituitary adenoma [1, 2]. This leads to
an overproduction of insulin-like growth factor-1 (IGF-1),
with consequent somatic overgrowth and physical disfig-
urement [3, 4]. Acromegaly can cause a variety of symp-
toms, such as sweating, headache, and joint pain [5], and is
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associated with severe comorbidities [3]. Diagnosis is
based on assessment of biochemical (GH and IGF-1) and
imaging (pituitary tumor) components, as well as clinical
features [3, 6]. The main treatment options are surgery and
long-acting somatostatin analogs in those who cannot be
cured with surgery or who are poor surgical candidates [3,
7, 8]. The goals of treatment are to ameliorate symptoms,
reduce morbidity and mortality, and control GH/IGF-1
hypersecretion and tumor growth [3, 8, 9]. However,
clinical features and the biochemical profiles may give
discordant information, which hampers diagnostic and
decision-making processes [3]. In addition, there may be
discrepancies between the results of GH and IGF-1 assays
[10, 11], further emphasizing the need for comprehensive
and integrative evaluation of all disease-specific
parameters.
Two patient-reported outcome (PRO) instruments are
currently available for assessing acromegaly: the Patient-
assessed Acromegaly Symptom Questionnaire (PASQ) [12]
and the Acromegaly Quality of Life (AcroQoL) question-
naire [13]. However, neither record the full spectrum of
features (biochemical, tumoral, and clinical) necessary to
optimally diagnose, stage and manage acromegaly. In
addition, a previous study has shown that the structure and
function of pituitary adenomas may be useful for classifying
acromegaly types [14]. Thus, there is a need for a compre-
hensive instrument that records biochemical, tumoral, and
clinical aspects of acromegaly. Two such instruments are
currently in development: SAGIT and ACRODAT
(ACROmegaly Disease Activity Tool) [15]. The SAGIT
instrument is multidimensional, comprising five sections
that assess key features of acromegaly [6]: signs and
symptoms (S), associated comorbidities (A), GH levels (G),
IGF-1 levels (I), and the Tumor profile (T) (Fig. 1a).
The SAGIT instrument was developed by a steering
committee comprising acromegaly experts from the Acro-
megaly Consensus Group, which has published guidelines
and consensus papers [16–20]). The aim was to provide a
reference instrument for acromegaly staging in clinical
practice. A global development program, involving an
iterative, 3-step process (NCT02231593), was imple-
mented to develop and validate the original SAGIT
instrument. Step 1 pre-testing evaluated ease of under-
standing and acceptability of the instrument and its layout
by future users (i.e. endocrinologists). In the Step 2 pilot
study, endocrinologists assessed the interface and also
content validity, relevance, and acceptability. The Step 3
clinical validation phase will consist of a large clinical
study to evaluate performance of the instrument, develop
scoring, determine score thresholds to stage patients and
assess treatment response, and develop decision indications
for patient management. Here, we report the methodology
and results from the pre-testing and pilot study steps.
Methods
The process for development and validation of the SAGIT
instrument (Supplemental Figure 1) was based on the
methodology of Arnould [21]. Members of the steering
committee were involved at all key milestones of the
project; after each step, a steering-committee meeting was
held to discuss the results and agree subsequent steps.
Step 1 pre-testing
The objectives of Step 1 pre-testing were: to assess prac-
tising endocrinologists’ understanding of the original ver-
sion of the SAGIT instrument and to assess its layout and
length; to explore understanding and acceptability in dif-
ferent countries; and to evaluate its relevance, ease of use,
applicability, and usefulness in practice.
Testing was conducted in Brazil, France, Germany,
Italy, Spain, and the UK using retrospective evaluation of
patients’ medical records. Twelve endocrinologists (two
per country) were asked to participate, each assessing de-
identified medical records of three patients. Endocrinolo-
gists were eligible for inclusion if they were currently
treating at least three patients with acromegaly and were
not familiar with the SAGIT instrument. Medical records
were included if patients were aged C18 years, had a
confirmed diagnosis of acromegaly, and had given consent
for the use of their (acromegaly) medical information.
Each endocrinologist was required to complete the
SAGIT instrument on two occasions for each patient [be-
fore and C3 months after an intervention (i.e. medical
treatment, surgery, or radiotherapy)]. Endocrinologists also
completed the evaluation form for the PRAgmatic Content
and face validity Test (PRAC-Test) and they participated
in a 1-h cognitive debriefing interview (conducted by
telephone) to assess their understanding and opinion of the
items in each section of the SAGIT instrument. The PRAC-
Test is a standardized, rigorously developed questionnaire
designed to systematically evaluate the qualities and limi-
tations of patient-reported outcomes instruments in clinical
practice [22]. It is also applicable to clinician-reported
outcome (ClinRO) instruments.
Step 2 pilot study
Following Step 1 pre-testing, the SAGIT instrument was
updated to reflect feedback from the endocrinologists. The
resulting SAGIT instrument (pilot version) was then tested
in the Step 2 pilot study. The objectives of the pilot study
were: to evaluate the updated version of the SAGIT instru-
ment in patients with acromegaly being actively managed in
real-time conditions in clinical practice; to evaluate the
acceptability of the updated instrument to practising
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endocrinologists and their intention to use it in clinical
practice; and to finalize an operational version of the SAGIT
instrument for use in the clinical validation study.
The pilot study used a prospective, multicenter, observa-
tional design in five countries (France, Germany, Italy, Spain,
and the USA), where ethics approval was obtained (Step 2
prospective pilot study). Endocrinologists in these countries
completed a copy of the SAGIT instrument for each patient, as
well as a copy of the PRAC-Test evaluation form. Due to
time constraints with ethics procedures in the UK and Brazil,
the retrospective design from Step 1 (i.e. using patient records
combined with a cognitive debriefing interview) was used in
these countries (Step 2 retrospective pilot study).
Fourteen endocrinologists (two per country) partici-
pated, and each was to assess three patients (or the medical
records of three patients): one treated patient with
stable/controlled acromegaly, one treated patient with
active/uncontrolled acromegaly, and one treatment-naı¨ve
patient. Inclusion criteria for the endocrinologists were the
same as Step 1; as familiarity with the SAGIT instrument
was an exclusion criterion, those who participated in Step 1
were not eligible to take part in Step 2. Patient selection
criteria were the same as those for Step 1; these and
specific inclusion criteria for stable/controlled, active/un-
controlled, and treatment-naı¨ve subgroups are summarized
in Table 1.
Fig. 1 Versions of the SAGIT instrument a used in Step 1 pre-testing (original version) and b following completion of Step 1 pre-testing and
Step 2 pilot study
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Fig. 1 continued




Characteristics of participating clinicians
Twelve endocrinologists were recruited; of these, 11
completed the SAGIT instrument (based on the medical
records of 33 patients) and the PRAC-Test questionnaire,
and 10 were interviewed. Participating endocrinologists
were aged 32–58 years, with most working in a hospital
environment (Table 2). The number of acromegaly patients
seen by the endocrinologists varied across participating
countries, from 2–5 per month in the UK to 10–60 per
month in Brazil (Supplemental Table 1).
Telephone interview
Endocrinologists indicated that the SAGIT instrument was
easy to use and understand and that it was simple to
complete. It was considered useful for clinical practice,
providing a standardized approach for assessing disease
progression and the effects of new interventions. Several
areas for improvement were identified, including: how to
report and interpret the score for each section; how to use
the information on severity ranking for the signs and
symptoms (S) and associated comorbidities (A); how the
scores could be used to guide patient management; and
correlation between scores and prognosis/treatment
recommendations.
Endocrinologists’ feedback on items in each section of
the SAGIT instrument is summarized in Supplemental
Table 2. This included: the proposal of additional signs and
symptoms and associated comorbidities; the subjectivity of
the severity ranking in these sections; and confusion on
how to report GH levels (specifically, whether one or both
measures were required).
PRAC-Test
Responses to the questions on the utility of the SAGIT
instrument are summarized in Fig. 2 and country-specific
Table 1 Patient inclusion criteria for the Step 2 pilot study
All patients:
• Male or female, C18 years of age
• Diagnosis of acromegaly confirmed by IGF-1 levels[1.3 times the ULN, GH levels[0.4 lg/L after an oral glucose load (75 g), and
presence of a pituitary adenoma on MRI (note that the diagnosis had to be suspected by a physician prior to testing and not an incidental
finding during work-up of non-pituitary or endocrine complaint)
• Cognitive and linguistic capacity to understand information provided on the conditions and objectives of the study
Controlled/stable patients:
• Patients who had received medical treatment or surgery C3 months previously
• Those with an MRI scan in the previous 12 months that reflected the current treatment phase (i.e. post-surgical or post-medical therapy) and
corresponded to the patient’s current disease status
• Those with stable, controlled biochemical disease, demonstrated by:
• C2 IGF-1 measurements within the normal range (both samples had to be taken prior to entry, C1 month apart, and during treatment with
the same medication regimen or post-surgery without medication)
• GH suppression to\0.4 lg/L following an oral glucose tolerance test (in patients who were post-surgical and not requiring medication) or
GH levels\ 1 lg/L (in those treated with somatostatin receptor ligands); patients treated with pegvisomant were not required to
demonstrate control by measurement of GH
• No history of non-compliance or inability to reliably receive treatment in the foreseeable future
• No gaps in treatment of[ 1 month within the 12 months prior to study entry
Patients with active/uncontrolled acromegaly:
• Patients who had received medical treatment or surgery C3 months previously
• Those with an MRI scan in the previous 3 months that reflected the patient’s current disease status
• Those with stable, controlled biochemical disease, demonstrated by:
• C2 IGF-1 measurements[1.3 9 ULN above the normal range on both occasions (both samples had to be taken prior to entry, C1 month
apart, and reflect the effect of the patient’s current treatment regimen [or a lower dose of the same medication] or the effect of the disease
prior to treatment initiation)
• GH levels[1 lg/L after surgery or before medication administration if surgery is not performed
Treatment-naı¨ve patients:
• Patients who had not received any form of treatment prior to study entry, including surgery, medication, or radiation.
GH growth hormone, IGF-1 insulin-like growth factor-1, MRI magnetic resonance imaging, ULN upper limit of normal
Pituitary (2016) 19:39–49 43
123
data are shown in Supplemental Table 3. Most endocri-
nologists reported that the instrument would be useful for
assessing the response to treatment (9/11) and as a com-
ponent of the medical record (7/11). None of the partici-
pants responded that the instrument would be of ‘no use’.
Responses on practical aspects of using the SAGIT
instrument are depicted in Fig. 3 (and for the individual
countries in Supplemental Table 4). Most endocrinologists
indicated that the instrument was concise (11/11), infor-
mative (10/11), quick to complete (10/10), easy to under-
stand (9/11), simple (9/10), practical (9/10), unbiased (9/
10), and precise (7/11). Most endocrinologists reported that
the instrument was not exhaustive (8/10). Four elements
were identified as requiring improvement: instructions for
completion, the response choices, the scores/decision rules,
and the interpretation/recommendations. Most participants
felt that the instrument required improvements; the number
of participants indicating that no further improvements
were needed was: title, 5/11; questions, 5/11; interpretation
and recommendations, 2/11; instructions, 1/11; response
choices, 1/11; score and decision rules, 1/11.
All endocrinologists reported that some parties would
benefit from using the SAGIT instrument, including the
scientific research community (10/11) and healthcare
Fig. 2 Utility of the SAGIT instrument: results of PRAC-Test questionnaire during Step 1 pre-testing and Step 2 pilot study. Note that multiple
responses were possible
Table 2 Characteristics of the endocrinologist population included in Step 1 pre-testing and Step 2 pilot study
Characteristics Step-1 pre-testing (n = 11) Step 2 pilot study
Prospective (n = 9) Retrospective (n = 4)
Age (years)a 32–58 34–56 38–48b
Mode of practice
Outpatient clinic 4 3 4
Hospital 9 8 0
Number of years treating acromegaly patientsa 2–30 3–30 10–19
Number of acromegaly patients seen per montha 2–60 3–15 1–80
Some endocrinologists worked in both outpatient clinics and hospitals. A breakdown of data by country are shown in Supplemental Table 1
a Range
b Missing data for one endocrinologist
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professionals (6/11). Three participants indicated that
patients could benefit and two that the pharmaceutical
industry could benefit.
When asked about reasons for not using the SAGIT
instrument, 8/11 endocrinologists selected one or more of
the following from a list of potential reasons: practicality
(1/11), lacks relevance for patients (2/11), lacks clinical
relevance (3/11), lacks scientific credibility (2/11), and
layout (1/11). Four endocrinologists indicated that there
was no reason not to use the instrument. In terms of their
willingness to use the SAGIT instrument, one participant
indicated that they would not use SAGIT with any of their
patients; the remainder would use it with a minority of their
patients (2/11), the majority of their patients (5/11), or all
of their patients (3/11). Furthermore, nine of the 11 en-
docrinologists would recommend the instrument to their
colleagues and 8/11 believed that they would have a pos-
itive reaction to it.
Most participants reported that it would be most
appropriate to complete the SAGIT instrument during a
patient consultation (7/11), while others noted that it would
be best completed between consultations (3/11) or in the
waiting room immediately before the consultation (2/11);
one participant responded ‘other’.
Following completion of the pre-testing step, the SAGIT
instrument was revised to take into account endocrinolo-
gists’ feedback. Revisions included addition of swelling to
the signs and symptoms section, addition of malignant
tumor to the associated comorbidities section, and
improved categorization of tumors in the tumor sec-
tion. Severity rankings were also removed and space was
provided to report the score for each section.
Step 2 pilot study
Characteristics of participating clinicians and their
patients
Of the 14 endocrinologists recruited, 13 participated in the
pilot study, four from Brazil and the UK, and nine from
other countries. Overall, 26 patients were included in the
prospective pilot study; in the UK and Brazil (retrospective
pilot study), the medical records of 12 patients were
evaluated. The ages of the participating endocrinologists
ranged from 34 to 56 years, with similar numbers working
in outpatient clinics and hospitals (Table 2). The number of
acromegaly patients encountered by the endocrinologists
varied from 1–10 per month in the UK to 12–80 per month
in Brazil (Supplemental Table 1).
Of the 26 patients whose data were analyzed in the pilot
study, nine had active/uncontrolled acromegaly, 10 had
stable/controlled acromegaly, and seven were treatment-
naı¨ve. Baseline characteristics of these patients are sum-
marized in Supplemental Table 5.
Use of SAGIT instrument to stage disease
The distribution of endocrinologists’ SAGIT scores
according to patients’ disease status is summarized in
Fig. 4. Most patients with stable/controlled disease were
characterized by a lack of signs and symptoms (6/9) and a
single comorbidity (5/10), a GH nadir following an oral
glucose tolerance test (OGTT) of B0.4 lg/L (2/2) or GH
random/series B1 lg/L (7/8), normal IGF-1 levels (9/10),
and no tumor (6/10). For those with active/uncontrolled
Fig. 3 Practical aspects of the
SAGIT instrument: results of
the PRAC-Test questionnaire
during Step 1 pre-testing and
Step 2 pilot study. Note that
multiple responses were
possible
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Fig. 4 Distribution of endocrinologists’ scores according to patients’ profiles (Step 2 pilot study; n = 26 patients)
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disease, most had one or two signs and symptoms (7/9), up
to three comorbidities (8/8), and IGF-1 levels
C1.3 9 ULN (7/9). GH levels (random/series) varied
between 1 and 10 lg/L, and distribution was scattered
across the tumor types. Most treatment-naı¨ve patients had
three or four signs and symptoms (6/7) and macro-in-
trasellar tumors [10 mm (5/7). All treatment-naı¨ve
patients had GH levels C2.5 lg/L (OGTT) or C5 lg/L
(random/series), and IGF-1 levels[2 9 ULN. There was
no consistent pattern in the number of comorbidities in
treatment-naı¨ve patients.
Telephone interview (UK and Brazil only)
Endocrinologists found the instrument to be straightfor-
ward and easy to complete, with no major challenges. The
scoring was easy to perform and report, but endocrinolo-
gists reported that management decision rules based on
scores were needed. Feedback on the sections of the
SAGIT instrument are summarized in Supplemental
Table 2.
PRAC-Test
Responses on the utility of the SAGIT instrument are
summarized in Fig. 2 and country-specific data are shown
in Supplemental Table 3. Most endocrinologists reported
that the instrument would be useful for scientific purposes
(10/13), to assess the response to treatment (8/13), and to
contribute to therapeutic decision-making (8/13). None of
the participants felt that the instrument would be of no use.
Responses on practical aspects of using SAGIT are
shown in Fig. 3 (and for the individual countries in Sup-
plemental Table 4). Most endocrinologists indicated that
the instrument was concise (12/13), unbiased (12/13),
simple (11/13), easy to understand (11/13), quick to com-
plete (11/13), and informative (10/13), and many consid-
ered it precise (9/13) and practical (8/12), although less
than half considered it exhaustive (6/13). Very few ele-
ments of the instrument were selected as requiring
improvement; exceptions were the response choices, score
and decision rules, and interpretation and recommenda-
tions. Some participants reported that the instrument
required further improvements; the numbers indicating that
no further improvement was needed for each section were
as follows: title, 10/13; instructions, 7/13; questions, 5/13;
scores and decision rules, 5/13; interpretation and recom-
mendations, 5/13; and response choices, 3/13.
All endocrinologists reported that some parties would
benefit from using the SAGIT instrument, including the
scientific research community (10/13) and healthcare pro-
fessionals (8/13). Five participants indicated that patients
could benefit, and one that the pharmaceutical industry
could benefit.
The following were given as reasons for not using the
SAGIT instrument: impractical (5/13), lack of relevance
for patients (2/13), lack of scientific credibility (2/13), and
lack of clinical relevance (2/13). Six endocrinologists
indicated that there was no reason not to use the instru-
ment. In terms of their willingness to use the instrument,
one participant indicated that he/she would not use it; the
remainder would use it with most patients (n = 6/13), a
minority of patients (n = 5/13), or all patients (n = 1/13).
Furthermore, 10 of the 13 endocrinologists would recom-
mend the instrument to their colleagues and 9/13 believed
that they would have a positive reaction to it.
Participants felt that it would be most appropriate to
complete the SAGIT instrument during a patient consul-
tation (9/13), between consultations (4/13), or in the
waiting room immediately before the consultation (1/13).
Following completion of the pilot study, the SAGIT
instrument was revised in response to feedback. Revisions
included a simplified scoring system for signs and symp-
toms (S) and associated comorbidities (A) and greater
emphasis on the need to report GH after OGTT or as
random/series measurement. The updated version of the
instrument to be used in the clinical validation study is
shown in Fig. 1b.
Discussion
SAGIT is a new ClinRO instrument, that is, it allows
‘‘assessment of the status of a patient’s health condition
based on clinician observation and interpretation’’ [23]. It
was developed by acromegaly experts and structured to
reflect key components associated with diagnosis and the
management of patients with acromegaly, namely signs
and symptoms (S), associated comorbidities (A), GH levels
(G), IGF-1 levels (I), and tumor profile (T). This original
version of the SAGIT instrument was field-tested, in line
with published methodology [21], with practising
endocrinologists managing patients with acromegaly using
an iterative, robust, and rigorous process consisting of pre-
testing and a subsequent pilot study. These two steps
allowed the content and layout of the instrument to be
tested in different settings, that is, retrospectively using
patients’ medical records and prospectively during a con-
sultation, at different timepoints (before and after an
intervention, and in real-time) and with different patient
profiles (stable/controlled, active/uncontrolled, and treat-
ment-naı¨ve).
Assessment of quality of life was not included in the
SAGIT instrument as this is best rated by patients them-
selves and therefore less suitable for a ClinRO instrument.
Pituitary (2016) 19:39–49 47
123
Furthermore, a patient-reported outcome instrument is
already available for assessing quality of life in acromegaly
(the AcroQoL questionnaire). To provide endocrinologists
with a comprehensive perspective of acromegaly status and
evolution, complementing the SAGIT instrument with a
PRO questionnaire would be recommended as this may add
an important dimension related to patient status. This is
particularly important in view of the frequent mismatch
between outcomes when reported by clinicians and
patients, an issue raised by some endocrinologists during
the cognitive debriefing in Step 1.
In the Step 1 pre-testing, the endocrinologists’ opinion
of the SAGIT instrument in its original version was uni-
formly favorable. In particular, participants acknowledged
the brevity, simplicity, rapidity, ease of use, objectivity,
and one-page format of the instrument, features essential to
endocrinologists if the instrument is to be used for patient
management in clinical practice. These results are
encouraging for an early-stage version of an outcome
instrument, particularly as scoring and interpretive rules
have yet to be developed. However, the pre-testing step
also identified general issues (e.g. how to report the score
for each section), as well as section-specific issues, such as
the utility of the severity ranking for signs and symptoms
and associated comorbidities. Methods of assessing GH
(i.e. either nadir following OGTT or random/series) also
required modification and clarification because of differ-
ences in practice across countries and according to patient
profiles.
Results of the pilot study, which was conducted mainly
in real-time, were encouraging, confirming the appropri-
ateness of the instrument for clinical practice in terms of
content, length, and rapidity of completion, and accept-
ability to endocrinologists. In particular, good consistency
between pre-determined stage, GH and IGF-1, and signs
and symptoms was reported. Interestingly, however, data
on tumor dimensions and comorbidities were less pre-
dictable based on GH and IGF-1 and on pre-selected stage
of the disease. This reinforces the concept that a compre-
hensive instrument may capture clinical features pertinent
to therapeutic decision-making that cannot be easily pre-
dicted based solely on biochemical evaluation/staging.
According to the endocrinologists who participated in Step
2, aspects of the instrument requiring improvement were
decision and interpretation rules, and recommendations for
patient management. The large-scale validation study (Step
3 clinical validation phase) will provide information nec-
essary to develop this guidance. As well as confirming the
practicality and utility of the instrument, the pilot study
provided preliminary evidence that the SAGIT instrument
differentiates between different profiles of patients with
acromegaly (stable/controlled disease, active/uncontrolled
disease, and treatment naive); this will also be explored
further in Step 3.
The relatively small numbers of participating endocri-
nologists limits comparisons between results obtained in
different countries. However, it is interesting that despite
cross-country differences in management and practice,
endocrinologists’ opinion and feedback was generally
similar across countries. The only exception to this was
observed in Step 1 pre-testing: two endocrinologists (from
Spain) had the most negative views of the instrument, and
the only participant who indicated that they would not be
willing to use the instrument in any patient was from Spain.
The link between disease severity and SAGIT scores was
questioned by one of these endocrinologists during the
interview, and may explain the scepticism. These findings
were not replicated in Step 2, and the use of the instrument
in real-time conditions on a larger scale (in the Step 3
clinical validation study) should test the results of the pilot
study.
Recently, ACRODAT (ACROmegaly Disease Activity
Tool) [15], a multidimensional instrument based on clinical
features but not GH levels, has been proposed. However,
information is limited and has not been published.
In the next phase of SAGIT, which will also be con-
ducted retrospectively using medical records as well as
prospectively in real-time, rules and recommendations for
treatment decision-making and patient management will be
defined. The ability of the instrument to discriminate
groups of patients with acromegaly (controlled versus not
controlled) and to define a new acromegaly staging based
on clinical, biochemical, and tumor parameters in the
instrument will also be assessed. The study will be con-
ducted in 35 centers in 10 countries worldwide and
enrolment of C200 patients is planned.
On the basis of the qualitative pilot testing phase, the
current content and format of the SAGIT instrument are
well accepted and understood by endocrinologists. SAGIT
is a promising instrument offering the potential for stan-
dardized classification and management of acromegaly,
thereby facilitating optimal patient management.
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